Objective:
To present 5-year data on pegcetacoplan treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), highlighting its significance in improving patient outcomes.
Approach:
- 67% patient retention in GALE; 74% excluding unrelated deaths.
- 24% overall reduction in GA growth across the entire population over 5 years.
- 3.9 mm² of retinal tissue preserved after 5 years, equating to over 1.5 disc areas.
- Early treatment preserved twice the retinal tissue compared to delayed treatment.
- Treatment saved approximately 1.5 years of disease progression.
- Projected sham methodology used due to all sham patients crossing over to active treatment after 24 months, which may affect the interpretation of efficacy results.
Key Findings:
Interpretation:
Pegcetacoplan demonstrates increasing benefits in tissue preservation over 5 years, with a consistent safety profile, suggesting its potential as a standard treatment for GA.
Limitations:
Conclusion:
Pegcetacoplan treatment effectively preserves retinal tissue and slows disease progression in GA, with a favorable safety profile, emphasizing the importance of early treatment initiation.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.